Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis

NCT01512277 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT01512277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01512277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis
Lead sponsor
University Hospital, Lille
Phase
Phase 1
Overall status
Completed
Start date
September 30, 1998
Completion date
September 30, 1999
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bilharziasis, schistosomiasis, urinary schistosomiasis